Cargando…

Low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients)

PURPOSE/OBJECTIVES: The aim of this study is to analyze the results of exclusive interstitial brachytherapy (IBT) as a conservative approach in the treatment of penile cancer confined to the glans or the shaft with long-term follow-up in a single institution. MATERIALS/METHODS: Between July 1992 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Cordoba, A., Escande, A., Lopez, S., Mortier, L., Mirabel, X., Coche-Déqueant, B., Lartigau, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964092/
https://www.ncbi.nlm.nih.gov/pubmed/27464910
http://dx.doi.org/10.1186/s13014-016-0676-9
_version_ 1782445044759789568
author Cordoba, A.
Escande, A.
Lopez, S.
Mortier, L.
Mirabel, X.
Coche-Déqueant, B.
Lartigau, E.
author_facet Cordoba, A.
Escande, A.
Lopez, S.
Mortier, L.
Mirabel, X.
Coche-Déqueant, B.
Lartigau, E.
author_sort Cordoba, A.
collection PubMed
description PURPOSE/OBJECTIVES: The aim of this study is to analyze the results of exclusive interstitial brachytherapy (IBT) as a conservative approach in the treatment of penile cancer confined to the glans or the shaft with long-term follow-up in a single institution. MATERIALS/METHODS: Between July 1992 and November 2013, 73 consecutive patients with non-metastatic invasive penile cancer were treated by Low dose rate (LDR) IBT in our institution. The localization of the primary lesion was glands in 67 patients (91.8 %) and shaft in 6 patients (8.2 %). All 73 patients presented with squamous cell carcinoma with grades of differentiation as follows: 34 patients with grade 1 (44.7 %), 9 patients with grade 2 (11.8 %), 9 patients with grade 3 (11.8 %) and 21 patients unknown (28.8 %). Six patients (7.8 %) presented with in situ carcinoma, 55 patients (75,3 %) presented with T1, 11 patients (15 %) presented with T2, and one patient (1.3 %) presented with Tx. Inguinal nodal dissection was performed in 29 patients (38.2 %); 13 patients (17.8 %) presented with histologically confirmed positive ganglion. After circumcision, IBT was performed using a hypodermic needle. The median dose delivered was 60 Gy (range, 40 to 70 Gy). The median activity of the iridium-192 wire was 1.12 mCi/cm, and the median reference isodose rate was 0.4 Gy/h (range, 0.2–1.2). Patients with histological inguinal metastases received external beam radiotherapy to the selected inguinal affected area with a median dose of 45 Gy (30–55 Gy). RESULTS: The median follow-up time was 51.8 months (range 34.4 to 68.7). The 5-year overall survival was 82.0 %, with eight deaths from cancer and five non-cancer-related deaths. Disease-specific survival was 91.4 %, relapse-free survival was 64.4 %, and local relapse-free survival as 74 %. Total or partial penile preservation was 87.9 % at 5-years. Complications rates at 5 years were 6.6 % urethral stenosis (five patients), two patients (2.6 %) with pain related to sexual intercourse and four patients (5.3 %) with dysuria grade 2. Five patients (6.8 %) required penile amputation for necrosis. CONCLUSIONS: IBT provides good local control with organ preservation, excellent tolerance and low complication rates in early-stage penile cancers.
format Online
Article
Text
id pubmed-4964092
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49640922016-07-29 Low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients) Cordoba, A. Escande, A. Lopez, S. Mortier, L. Mirabel, X. Coche-Déqueant, B. Lartigau, E. Radiat Oncol Research PURPOSE/OBJECTIVES: The aim of this study is to analyze the results of exclusive interstitial brachytherapy (IBT) as a conservative approach in the treatment of penile cancer confined to the glans or the shaft with long-term follow-up in a single institution. MATERIALS/METHODS: Between July 1992 and November 2013, 73 consecutive patients with non-metastatic invasive penile cancer were treated by Low dose rate (LDR) IBT in our institution. The localization of the primary lesion was glands in 67 patients (91.8 %) and shaft in 6 patients (8.2 %). All 73 patients presented with squamous cell carcinoma with grades of differentiation as follows: 34 patients with grade 1 (44.7 %), 9 patients with grade 2 (11.8 %), 9 patients with grade 3 (11.8 %) and 21 patients unknown (28.8 %). Six patients (7.8 %) presented with in situ carcinoma, 55 patients (75,3 %) presented with T1, 11 patients (15 %) presented with T2, and one patient (1.3 %) presented with Tx. Inguinal nodal dissection was performed in 29 patients (38.2 %); 13 patients (17.8 %) presented with histologically confirmed positive ganglion. After circumcision, IBT was performed using a hypodermic needle. The median dose delivered was 60 Gy (range, 40 to 70 Gy). The median activity of the iridium-192 wire was 1.12 mCi/cm, and the median reference isodose rate was 0.4 Gy/h (range, 0.2–1.2). Patients with histological inguinal metastases received external beam radiotherapy to the selected inguinal affected area with a median dose of 45 Gy (30–55 Gy). RESULTS: The median follow-up time was 51.8 months (range 34.4 to 68.7). The 5-year overall survival was 82.0 %, with eight deaths from cancer and five non-cancer-related deaths. Disease-specific survival was 91.4 %, relapse-free survival was 64.4 %, and local relapse-free survival as 74 %. Total or partial penile preservation was 87.9 % at 5-years. Complications rates at 5 years were 6.6 % urethral stenosis (five patients), two patients (2.6 %) with pain related to sexual intercourse and four patients (5.3 %) with dysuria grade 2. Five patients (6.8 %) required penile amputation for necrosis. CONCLUSIONS: IBT provides good local control with organ preservation, excellent tolerance and low complication rates in early-stage penile cancers. BioMed Central 2016-07-27 /pmc/articles/PMC4964092/ /pubmed/27464910 http://dx.doi.org/10.1186/s13014-016-0676-9 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Cordoba, A.
Escande, A.
Lopez, S.
Mortier, L.
Mirabel, X.
Coche-Déqueant, B.
Lartigau, E.
Low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients)
title Low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients)
title_full Low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients)
title_fullStr Low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients)
title_full_unstemmed Low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients)
title_short Low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients)
title_sort low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964092/
https://www.ncbi.nlm.nih.gov/pubmed/27464910
http://dx.doi.org/10.1186/s13014-016-0676-9
work_keys_str_mv AT cordobaa lowdosebrachytherapyforearlystagepenilecancera20yearsingleinstitutionstudy73patients
AT escandea lowdosebrachytherapyforearlystagepenilecancera20yearsingleinstitutionstudy73patients
AT lopezs lowdosebrachytherapyforearlystagepenilecancera20yearsingleinstitutionstudy73patients
AT mortierl lowdosebrachytherapyforearlystagepenilecancera20yearsingleinstitutionstudy73patients
AT mirabelx lowdosebrachytherapyforearlystagepenilecancera20yearsingleinstitutionstudy73patients
AT cochedequeantb lowdosebrachytherapyforearlystagepenilecancera20yearsingleinstitutionstudy73patients
AT lartigaue lowdosebrachytherapyforearlystagepenilecancera20yearsingleinstitutionstudy73patients